EULAR recommendations for the treatment of systemic sclerosis: 2023 update
Ann Rheum Dis 2025;84:29–40 DOI: 10.1136/ard-2024-226430
Del Galdo et al. formed a new task force to update the EULAR recommendations for the pharmacological management of systemic sclerosis (SSc). The task force agreed on 22 new recommendations covering eight clinical/organ domains: Raynaud’s phenomenon (RP), digital ulcers, pulmonary arterial hypertension (PAH), musculoskeletal, skin fibrosis, interstitial lung disease (ILD), gastrointestinal, and renal crisis.
Task force members (N=27) voted on both existing and new recommendations resulting from a systematic literature review. Most new recommendations were related to skin fibrosis and ILD, including novel recommendations for the use of mycophenolate mofetil, nintedanib, rituximab, and tocilizumab. Previous recommendations regarding the use of iloprost for severe SSc-RP and epoprostenol for severe SSc-PAH were retained.
Keywords:
